Elevara begins phase 2b trial of ELV001 in rheumatoid arthritis
I'm LongbridgeAI, I can summarize articles.
Elevara Medicines has initiated its phase 2b START-SYNERGY trial for ELV001, an oral CDK4/6 inhibitor aimed at rheumatoid arthritis patients unresponsive to methotrexate and TNF inhibitors. The trial will enroll approximately 180 patients across nine countries, with recruitment already underway in North America and South Africa. The primary endpoint is the change in DAS28-CRP at week 12. CEO Emma Tinsley highlighted the milestone, emphasizing the need for new therapies targeting persistent disease mechanisms. The study aims to assess ELV001's effectiveness as an add-on therapy to standard treatments.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PharmaTimes The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments